|
Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial. |
|
|
Honoraria - Amgen; Genesis Pharma; Janssen Oncology; Pfizer; Prothena; Takeda |
Consulting or Advisory Role - Amgen; Genesis Pharma; Janssen Oncology; Pfizer; Prothena; Takeda |
Research Funding - Amgen (Inst); Janssen Oncology (Inst) |
Travel, Accommodations, Expenses - Genesis Pharma; Janssen Oncology; Pfizer; Takeda |
|
|
Consulting or Advisory Role - Janssen Research & Development |
Research Funding - Alnylam (Inst); Celgene (Inst); Janssen Oncology (Inst); Pfizer (Inst); Prothena; Takeda (Inst) |
Travel, Accommodations, Expenses - Janssen Oncology; Pfizer; Prothena |
|
|
Honoraria - Celgene; GlaxoSmithKline; Janssen-Cilag; Takeda |
|
|
|
Honoraria - Janssen; Prothena |
Consulting or Advisory Role - Janssen; Prothena; Takeda |
Research Funding - Janssen; Prothena |
Travel, Accommodations, Expenses - Janssen; Merck Sharp & Dohme; Prothena; Sanofi; Takeda |
|
|
Honoraria - Amgen; Celgene; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Takeda |
Research Funding - Abbvie; Amgen; Celgene; Janssen; Takeda |
|
|
Consulting or Advisory Role - Abbvie; Caelum Biosciences; Janssen Research & Development; Proclara |
Research Funding - Celgene (Inst); Janssen (Inst); Oncopeptides (Inst); Prothena (Inst); Takeda (Inst) |
|
|
Consulting or Advisory Role - Caelum Biosciences; Celgene; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Takeda |
Research Funding - Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Ono Pharmaceutical; Sanofi; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Takeda |
Research Funding - Celgene |
|
|
Consulting or Advisory Role - Janssen Oncology; Sanofi/Aventis; Takeda |
Research Funding - Janssen Oncology |
Patents, Royalties, Other Intellectual Property - TMC534 siRNA to knockdown Ig expression |
|
|
|
Consulting or Advisory Role - Janssen |
Travel, Accommodations, Expenses - Celgene |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Millennium |
|
|
|
Leadership - Viracta Therapeutics |
Stock and Other Ownership Interests - Viracta Therapeutics |
Patents, Royalties, Other Intellectual Property - Viracta Therapeutics |
|
|
Travel, Accommodations, Expenses - Janssen |